Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (111)	4/17/1998 8:25:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 4974

<<Biotechnology Value Fund L.P. has a 5.5% investment stake in Aquila Biopharmaceuticals Inc. (AQLA)>> I wonder if our house immunologist would care to comment on AQLA? <G> There's a write-up of their technology in a recent S-3 they filed, for those that want to check it out. Peter

To: Vector1 who wrote (111)	4/18/1998 12:32:00 PM
From: scaram(o)uche	Respond to of 4974

V1: I've followed the development of AQLA's saponin derivative adjuvant since it was in early development. Rick Coughlin, who did much of the early work, was hired from Centocor as Section Manager, Immunology at what was then Cambridge Biotech. Don't know if he's still there, but, if so, he'd make a good contact. Always thought that the adjuvant was better than those in development at CYTR or RIBI, but, after the bankruptcy, I never thought that they'd bounce back so successfully. The 10-K must be a nightmare to get through. Thanks! Rick